Ballistic gelatin calibration standardisation.

basic sciences biophysics statistics & research methods

Journal

BMJ military health
ISSN: 2633-3775
Titre abrégé: BMJ Mil Health
Pays: England
ID NLM: 101761581

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 06 02 2020
revised: 16 02 2020
accepted: 23 02 2020
pubmed: 15 3 2020
medline: 1 4 2022
entrez: 15 3 2020
Statut: ppublish

Résumé

A review of ballistic gelatin calibration standards has highlighted that data used from studies with different calibrations methods may not be able to be compared. Calibration of ballistic gelatin did not occur until the mid-1980s when Fackler recognised the deficiencies of uncalibrated gelatin. He determined that the calibration standard should be 85±5 mm of ball bearing penetration for a 180 m/s impact velocity. This study looks to improve on and optimise current ballistic gelatin calibration standards METHODS: Nine 0.177 cal (4.5 mm) spheres were fired using a Daisy Powerline air rifle at velocities between 134 m/s and 224 m/s at 25 gelatin blocks (n=225). Velocities were measured using an The R-squared regression model showed that all batches had a close fit to the regression line. Using the R-squared regression model, the equation y=0.584x - 20.02 (where x is the velocity) returned a DoP of 84.918 mm for a 180 m/s impact and therefore needed minimal adjustment to align with Fackler's 85 mm DoP. The equation can be adjusted to y=0.584x - 20.12 to return a DoP of 85 mm for 180 m/s. We propose that the calibration standard of ballistic gelatin with 4.5 mm spheres is DoP=0.584x - 20.12 where DoP is the depth of penetration (mm) and x is the impact velocity (m/s), The measured DoP should be within 5% of the calculated DoP.

Identifiants

pubmed: 32169950
pii: bmjmilitary-2020-001430
doi: 10.1136/bmjmilitary-2020-001430
doi:

Substances chimiques

Gelatin 9000-70-8

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-127

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Amy Pullen (A)

University of Otago Christchurch, Christchurch, New Zealand a.pullen@dta.mil.nz.

D C Kieser (DC)

University of Otago Christchurch, Christchurch, New Zealand.
Medical Corps, New Zealand Defence Force, Christchurch, New Zealand.

G Hooper (G)

University of Otago Christchurch, Christchurch, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH